Using an Oral Anti-Inflammatory Drug to Improve Treatment Options for DME & DR Patients Non-Responsive to Anti-VEGF Therapy
Time: 11:00 am
day: Day Two
Details:
- Addressing the unmet need in DR and DME patients receiving anti-VEGF treatment by targeting non-responders with Xiflam, a once-daily oral small molecule that inhibits the pathologically open Connexin43 (Cx43) hemichannel
- Demonstrating positive preclinical results, Xiflam shows promise in modulating the dysregulated inflammasome pathway, reducing autoinflammation in DME and DR
- Exploring the benefits of oral administration over injections, particularly for early-stage disease patients who prefer non-invasive treatment options
